Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
NVIDIA
NVDA
|
$1.06B |
| 2 |
Apple
AAPL
|
$625M |
| 3 |
UnitedHealth
UNH
|
$201M |
| 4 |
Cisco
CSCO
|
$192M |
| 5 |
Johnson & Johnson
JNJ
|
$182M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$608M |
| 2 |
Broadcom
AVGO
|
$240M |
| 3 |
United Rentals
URI
|
$212M |
| 4 |
CRH
CRH
|
$200M |
| 5 |
Pfizer
PFE
|
$174M |
Sector Composition
| 1 | Technology | 18.69% |
| 2 | Financials | 17.09% |
| 3 | Industrials | 13.01% |
| 4 | Consumer Discretionary | 11.1% |
| 5 | Healthcare | 10.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3051
Rentokil
RTO
$12.8B
| $480K | ﹤0.01% |
15,917
+964
| +6% | +$29.1K |
|
3052
NovoCure
NVCR
$1.37B
| $476K | ﹤0.01% |
30,449
-6,762
| -18% | -$106K |
|
3053
Melco Resorts & Entertainment
MLCO
$3.8B
| $473K | ﹤0.01% |
65,560
-1,868
| -3% | -$13.5K |
|
3054
The Beauty Health Co
SKIN
$260M
| $472K | ﹤0.01% |
106,415
-1,128
| -1% | -$5.01K |
|
3055
Ultragenyx Pharmaceutical
RARE
$3.07B
| $468K | ﹤0.01% |
10,017
-34,623
| -78% | -$1.62M |
|
3056
PMV Pharmaceuticals
PMVP
$77.4M
| $464K | ﹤0.01% |
272,859
-284,612
| -51% | -$484K |
|
3057
CF Bankshares
CFBK
$160M
| $461K | ﹤0.01% |
23,071
+1,128
| +5% | +$22.5K |
|
3058
Baytex Energy
BTE
$1.67B
| $460K | ﹤0.01% |
126,856
-50,041
| -28% | -$182K |
|
|
SRG
3059
Seritage Growth Properties
SRG
$211M
| $458K | ﹤0.01% |
47,457
+5,532
| +13% | +$53.4K |
|
3060
Grupo SIMEC
SIM
| $453K | ﹤0.01% |
14,058
| – | – |
|
3061
Kingstone Companies
KINS
$194M
| $453K | ﹤0.01% |
101,852
+6,816
| +7% | +$30.3K |
|
3062
United Bancorp
UBCP
$84.6M
| $446K | ﹤0.01% |
30,801
| – | – |
|
3063
Adicet Bio
ACET
$60M
| $445K | ﹤0.01% |
189,327
+35,913
| +23% | +$84.4K |
|
3064
Sight Sciences
SGHT
$193M
| $443K | ﹤0.01% |
83,866
| – | – |
|
|
JBIO
3065
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| $442K | ﹤0.01% |
427
| – | – |
|
3066
Travere Therapeutics
TVTX
$1.93B
| $437K | ﹤0.01% |
56,681
+702
| +1% | +$5.41K |
|
3067
McEwen Inc.
MUX
$734M
| $437K | ﹤0.01% |
44,303
| – | – |
|
|
NEXN
3068
Nexxen International
NEXN
$627M
| $434K | ﹤0.01% |
83,209
-1,721
| -2% | -$8.98K |
|
3069
Pyxis Oncology
PYXS
$118M
| $434K | ﹤0.01% |
101,810
| – | – |
|
3070
Cabaletta Bio
CABA
$155M
| $433K | ﹤0.01% |
25,375
| – | – |
|
|
LBPH
3071
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $431K | ﹤0.01% |
19,974
-12,773
| -39% | -$276K |
|
3072
Genasys
GNSS
$89.4M
| $430K | ﹤0.01% |
181,442
-77,414
| -30% | -$183K |
|
3073
Natural Health Trends
NHTC
$52.6M
| $430K | ﹤0.01% |
64,177
+12,800
| +25% | +$85.8K |
|
3074
Bank First Corp
BFC
$1.26B
| $423K | ﹤0.01% |
4,876
+129
| +3% | +$11.2K |
|
3075
Smart Sand
SND
$75.9M
| $420K | ﹤0.01% |
219,859
-31,571
| -13% | -$60.3K |
|